1. Home
  2. USGO vs CGTX Comparison

USGO vs CGTX Comparison

Compare USGO & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

USGO

U.S. GoldMining Inc.

HOLD

Current Price

$8.26

Market Cap

138.1M

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.43

Market Cap

110.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
USGO
CGTX
Founded
2015
2007
Country
United States
United States
Employees
10
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
138.1M
110.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
USGO
CGTX
Price
$8.26
$1.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$30.75
$3.33
AVG Volume (30 Days)
52.3K
1.1M
Earning Date
05-08-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.42
$0.25
52 Week High
$17.98
$3.83

Technical Indicators

Market Signals
Indicator
USGO
CGTX
Relative Strength Index (RSI) 32.17 64.39
Support Level $7.55 $1.29
Resistance Level $9.80 $1.53
Average True Range (ATR) 0.64 0.13
MACD 0.02 0.01
Stochastic Oscillator 28.61 81.58

Price Performance

Historical Comparison
USGO
CGTX

About USGO U.S. GoldMining Inc.

US Goldmining Inc is a mineral exploration company with a focus on the exploration and development of a project located in Alaska, USA. The company's primary asset is the 100%-owned Whistler exploration property located in Alaska, USA. It operates and reports in one segment, which focuses on the exploration and development of mineral properties.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: